What Olfera does

Olfera is a development-stage biopharmaceutical company founded in 2022 and headquartered in Mountain View, California, that is building an olfactory-based platform for drug discovery, optimization, and delivery targeting neurological disorders. The company's core technical premise is that the olfactory system provides a direct anatomical pathway to the brain, enabling therapeutics to circumvent the blood-brain barrier — a limitation the company cites as allowing only 0.1–0.2% of injected neurological antibodies and therapeutic proteins to reach their target. The platform combines advanced screening technology and pioneering chemistry to transform existing FDA-approved and promising neurological drugs into formulations optimized for nasal administration and rapid brain uptake, with stated use cases spanning epilepsy (fast-acting drugs reaching the brain within seconds), dementia (caregiver-friendly nasal sprays), and drugs with challenging oral side-effect profiles.

The leadership team consists of five members: CEO and co-founder Parnian Lak (PharmD, PhD), CTO Renaud Renault (PhD), Chief Science Advisor Kelvin Cooper (PhD), Chief Medical Advisor Zara Patel (MD), and Drug Delivery Expert Brian Kopec (PhD). The team is structured for translational science rather than commercial operations, and the company has no disclosed products, customers, partnerships, patents, or regulatory milestones in the source material.

Olfera's business model is not yet defined in commercial terms. As a pre-clinical biotech with no marketed products, pricing, distribution channels, and revenue mechanics remain undetermined; the company has disclosed $500,000 in funding from Orbital Edge Accelerator (July 2025) and participation in the SkyDeck Berkeley accelerator (2025). Its addressable market is framed around the 15% of the global population affected by neurological disorders and the $1.7 trillion in economic costs attributable to major neurological diseases, but no segment-specific capture, licensing strategy, or go-to-market plan is publicly documented.

Name

Olfera

Website

https://olferatx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Olfera is a development-stage biotech building an olfactory drug delivery platform that bypasses the blood-brain barrier to treat neurological disorders including epilepsy and dementia, serving patients and caregivers via nasal spray formulations of repurposed FDA-approved drugs.

Ownership category

akta.pro rank

Product category

Neurological Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

akta.pro secondary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Olfactory drug delivery
• Neurological therapeutics
• Biopharmaceutical platform
• Nasal spray drugs
• Blood-brain barrier

Headquarters

HQ city

Mountain View

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Marketing channels1 record

Core offering

Olfera develops a proprietary olfactory drug delivery platform that uses the olfactory system as a direct, non-invasive pathway to the brain, bypassing the blood-brain barrier. The platform enables the discovery, optimization, and delivery of neurological therapeutics by transforming existing FDA-approved and promising neurological drugs into effective, safe, and easy-to-administer treatments via advanced screening technology and pioneering chemistry. Example applications include fast-acting epilepsy drugs that reach the brain within seconds and nasal spray formulations for dementia patients and their caregivers.

Product overview

Olfera offers a single unified olfactory drug delivery platform rather than distinct named products. This platform enables drug discovery, optimization, and delivery by leveraging the olfactory system as a pathway to the brain that bypasses the blood-brain barrier. The company specializes in transforming existing FDA-approved neurological drugs into effective, safe, and easy-to-administer treatments through advanced screening technology and pioneering chemistry. Example therapeutic applications mentioned include fast-acting drugs to halt epilepsy (potentially reaching the brain within seconds) and medications optimized for nasal spray administration for dementia patients. The platform is designed to work with all major drug modalities and addresses the limitation that only 0.1-0.2% of injected neurological antibodies and therapeutic proteins typically reach their target when delivered through conventional methods.

Differentiator

Problem solved

Functional benefit

Products and services

• Olfactory Drug Delivery Platform A proprietary drug discovery, optimization, and delivery platform that uses the olfactory system as a direct pathway to the brain, bypassing the blood-brain barrier to transform existing FDA-approved and promising neurological drugs into non-invasive, safe, and easy-to-administer treatments. Compatible with all major drug modalities, it supports applications including fast-acting epilepsy drugs that reach the brain within seconds, dementia medications optimized for nasal spray administration, and brain delivery of drugs with challenging oral side effects. Intended for biopharmaceutical development targeting neurological conditions such as epilepsy and dementia.

Quantifiable outcome

• Currently only 0.1-0.2% of injected neurological antibodies reach their target; Olfera's platform aims to significantly improve this delivery rate

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators3 records

Recent moves3 records

Expansion highlights3 records

Direct peers

• Impel NeuroPharma: Was a clinical-stage biotech specializing in intranasal/upper-nasal drug delivery to the CNS using its proprietary Precision Olfactory Delivery (POD®) technology — the most direct historical peer to Olfera's olfactory delivery thesis. Provides a useful benchmark for both the opportunity and the historical execution challenges in translating nasal CNS delivery.
• Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative and lysosomal storage diseases, including the Enzyme Transport Vehicle (ETV) platform designed to cross the BBB and deliver biologics to the brain. Most direct comparably-sized peer pursuing engineered BBB-crossing delivery for CNS biologics.
• ArmaGen: Pre-clinical/clinical biotech developing antibody-based therapeutics that cross the BBB via receptor-mediated transcytosis using the transferrin receptor — a parallel BBB-shuttle approach to delivering biologics to the CNS, directly competing with Olfera's olfactory route thesis.

Broad incumbents

• Biohaven Pharmaceuticals: Commercial-stage CNS biotech (now part of Pfizer) focused on neurological and neuropsychiatric diseases including migraine, epilepsy, and rare CNS disorders — relevant as a larger incumbent that has invested in intranasal CNS delivery and provides a comparison point for commercial CNS asset value.
• Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based therapies for CNS diseases such as Parkinson's, Huntington's, and ALS — comparable as a platform-oriented CNS biotech tackling the BBB-delivery problem with an alternative modality (gene therapy), useful for platform-valuation triangulation.
• Sage Therapeutics: Biopharma developing CNS therapeutics including Zurzuvae (postpartum depression) and epilepsy programs — comparable as a CNS-focused biotech whose commercial trajectories illustrate the value of differentiated CNS delivery / mechanism approaches.

Emerging players

• Neumora Therapeutics: Clinical-stage neuroscience biotech pursuing precision medicine approaches for brain diseases, combining novel targets with brain-penetrant chemistry. Comparable as a well-funded platform biotech tackling CNS indications where delivery/bioavailability is a central challenge.
• Ovid Therapeutics: Clinical-stage biopharma developing small-molecule therapies for rare neurological and developmental disorders including epilepsies and Angelman syndrome. Comparable as a CNS-focused biotech where nasal/alternative delivery could be a meaningful strategic extension.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/olfera

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Olfera